Not Yet RecruitingPhase 4ACTRN12617001122347

The Effect of vaginal Bromocriptine in controlling Adenomyosis symptoms


Sponsor

Nahed ezzat allam

Enrollment

68 participants

Start Date

Feb 5, 2019

Study Type

Interventional

Conditions

Summary

Hysterectomy (removal of womb and ovaries)considered the most common treatment for symptomatic adenomyosis. However due to its association with perioperative , postoperative morbidity, decreased quality of life and high healthcare costs,it looks wise to find another non surgical treatment. Hysterectomy is also not appropriate for women who wish to preserve their fertility and availability of a noninvasive approach for the treatment of adenomyosis may be preferable for most women and could reduce the burden on healthcare systems by a major reduction in surgical intervention. Untill now no proved evidence for any mode of treatment. this study tried to find appropriate medical treatment for this problem.


Eligibility

Sex: FemalesMin Age: 23 YearssMax Age: 49 Yearss

Inclusion Criteria1

  • women complaining of symptoms related to presence of adenomyosis like dysmenorrhea, menstrual irregularities and or subfertility.

Exclusion Criteria5

  • -Patients on hormonal or intrauterine device as contraception
  • -Active pelvic infection
  • - Pregnant or breast fed women
  • -Hypersenstivity or contraindication to bromocriptine,
  • -local contraception users

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

vaginal bromocriptine suppository 0.5 mg twice daily inserted by patient for six months, the patient will be phoned monthly to monitor adherence to the intervention

vaginal bromocriptine suppository 0.5 mg twice daily inserted by patient for six months, the patient will be phoned monthly to monitor adherence to the intervention


Locations(1)

cairo, Egypt

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12617001122347